8-K: EyePoint Completes Pivotal Phase 3 Enrollment for DURAVYU in Wet AMD, Ahead of Schedule

EyePoint Pharmaceuticals announced the successful and early completion of enrollment for its pivotal Phase 3 LUCIA trial, marking the full enrollment of its DURAVYU program for wet age-related macular degeneration.

Summary

• Completed enrollment in the LUCIA trial, the second of two identical pivotal Phase 3 non-inferiority trials evaluating DURAVYU for the treatment of wet age-related macular degeneration (wet AMD).
• The first pivotal trial, LUGANO, completed enrollment in May 2025.
• Over 800 patients have been enrolled and randomized across the LUGANO and LUCIA trials, making DURAVYU one of the fastest enrolling Phase 3 pivotal programs for wet AMD.
• The LUCIA trial alone enrolled and randomized over 400 patients in seven months.
• Interim masked safety data from LUGANO and LUCIA is consistent with previous DURAVYU clinical trials, with no DURAVYU related ocular or systemic serious adverse events observed in over 190 patients across four trials.
• An independent Data Safety Monitoring Committee (DSMC) convened and recommended continuation of the program as planned.
• Topline 56-week data for LUGANO is expected in mid-2026, with LUCIA data to follow closely thereafter.
• DURAVYU is designed for 6-month redosing via a standard intravitreal injection in the physician's office.
• The primary endpoint of the Phase 3 pivotal trials is the average change in best corrected visual acuity (BCVA) at weeks 52 and 56 versus baseline.
• DURAVYU is also being evaluated for diabetic macular edema (DME), with positive Phase 2 VERONA trial results and a positive End-of-Phase 2 meeting with the FDA completed, supporting advancement to a Phase 3 pivotal program.

Sentiment

Score: 8

Explanation: The filing announces the successful and early completion of enrollment for pivotal Phase 3 trials, a significant de-risking event for a biopharmaceutical company. Positive interim safety data and strong cash runway further enhance the positive sentiment, despite inherent risks in drug development.

Positives

• Completed enrollment for both pivotal Phase 3 trials (LUGANO and LUCIA) for DURAVYU in wet AMD, significantly ahead of expectations.
• Rapid enrollment pace (over 800 patients across two trials, LUCIA enrolled over 400 patients in seven months) demonstrates strong enthusiasm from patients and physicians for DURAVYU's differentiated profile.
• Interim safety data is consistent with previous trials, showing a favorable safety and tolerability profile with no DURAVYU related ocular or systemic serious adverse events observed in over 190 patients.
• An independent Data Safety Monitoring Committee (DSMC) recommended continuation of the program as planned, reinforcing confidence in the trial's safety and design.
• The Phase 3 pivotal program was developed in alignment with the U.S. FDA and European Medicines Agency (EMA), enhancing potential for regulatory and commercial success.
• DURAVYU offers the potential for 6-month redosing, which could significantly reduce treatment burden compared to current standard of care (average every two months).
• Positive Phase 2 VERONA trial results for DME, meeting primary and secondary endpoints, with a positive End-of-Phase 2 meeting with the FDA completed, supporting advancement to Phase 3.
• Strong cash position of $318 million as of March 31, 2025, providing cash runway into 2027, past Phase 3 pivotal data in 2026.
• The company has a state-of-the-art cGMP manufacturing facility in Northbridge, MA, built to US FDA and EU EMA standards, with registration batches underway to support future NDA filing.

Risks

• Timing, progress, and results of clinical development activities, including DURAVYU, are uncertain.
• Uncertainties and delays relate to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval for commercialization of DURAVYU.
• Unanticipated costs and expenses may arise during development and commercialization.
• Cash and cash equivalents may not be sufficient to support the operating plan for as long as anticipated.
• Results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change.
• Unexpected safety or efficacy data could be observed during clinical trials.
• Uncertainties exist related to the regulatory authorization or approval process and available development and regulatory pathways for approval of product candidates.
• Changes in the regulatory environment could impact development and approval timelines.
• Disruptions at the FDA, including due to a reduction in its workforce and/or inadequate funding, could cause delays.
• Changes in U.S. and international trade policies may affect operations.
• Changes in expected or existing competition could impact market potential.
• The success of current and future license agreements is not guaranteed.
• Dependence on contract research organizations and other outside vendors and service providers poses risks.
• Product liability risks are inherent in pharmaceutical development.
• The impact of general business and economic conditions could affect financial performance.
• Protection of intellectual property and avoiding intellectual property infringement are critical challenges.
• Retention of key personnel is essential for continued progress.
• Delays, interruptions, or failures in the manufacture and supply of product candidates could occur.
• The availability of and the need for additional financing may arise.
• The ability to obtain additional funding to support clinical development programs is uncertain.
• Uncertainties exist regarding the timing and results of the August 2022 subpoena from the U.S. Attorneys Office for the District of Massachusetts.
• Uncertainties exist regarding the FDA warning letter pertaining to the Watertown, MA manufacturing facility.

Future Outlook

EyePoint Pharmaceuticals anticipates topline 56-week data for the LUGANO trial in mid-2026, with the LUCIA trial data to follow closely. The company expects to advance its DME program to a Phase 3 pivotal program in 2026. Management believes DURAVYU has the potential to be the first sustained-release TKI for wet AMD on the market and to shift the treatment paradigm for both wet AMD and DME, improving patient outcomes.

Management Comments

• "With enrollment now complete for our Phase 3 wet AMD program, well ahead of our expectations, we continue to demonstrate exceptional execution and our deep commitment to the retinal disease community." Jay S. Duker, M.D., President and Chief Executive Officer.
• "The industry-leading pace of our clinical program is a testament to the patient and physician enthusiasm for innovative, novel and more durable wet AMD treatments and DURAVYUs compelling and differentiated profile." Jay S. Duker, M.D., President and Chief Executive Officer.
• "As we look ahead to anticipated topline data for LUGANO in mid-2026 and LUCIA to follow, we remain focused on bringing the first sustained-release TKI for wet AMD to market and advancing our mission of delivering transformative treatment options for patients." Jay S. Duker, M.D., President and Chief Executive Officer.
• "Similar to our LUGANO trial, LUCIA has exceeded enrollment timelines, underscoring our clinical development leadership and continued recognition by the retinal community of DURAVYUs best-in-class profile." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer.
• "We are proud of the clinical rigor and patient-centric approach underpinning our Phase 3 program, including our real-world design, which has now been approved by both the U.S. and European regulatory bodies, as well as use of an on-label standard of care comparator that resonates with physicians." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer.
• "LUCIA also marked our expansion beyond the U.S. with patient participation in South America, Europe, Israel, Australia and India, demonstrating global momentum and interest in DURAVYU." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer.
• "The rapid enrollment of the LUCIA trial reflects its patient-centric design, DURAVYUs excellent safety profile, and EyePoints ongoing engagement with the retinal community." Anat Loewenstein, M.D., MHA, Vice President Ambulatory Services, Head of Retina Tel Aviv Medical Center, President of European Society of Retina Specialists (EURetina) and member of EyePoint’s Scientific Advisory Board.
• "With its use of a non-inferiority design and on-label aflibercept control, EyePoints Phase 3 program is designed to generate data that is relevant to clinical practitioners like myself." Anat Loewenstein, M.D., MHA.
• "Additionally, the 6-month redosing schedule being evaluated would enable greater clinical flexibility and improved compliance for patients, representing a potential paradigm shift for the treatment of wet AMD." Anat Loewenstein, M.D., MHA.

Industry Context

Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss requiring continuous, lifelong treatment. Current standard-of-care anti-VEGF treatments are typically dosed on average every two months in the United States, leading to significant patient and physician burden, potential non-compliance, and long-term vision loss. DURAVYU, as a sustained-release tyrosine kinase inhibitor (TKI), aims to address this unmet need by offering a 6-month redosing schedule, potentially shifting the treatment paradigm and improving patient compliance and outcomes. The company also highlights the large market opportunity and significant unmet need for more durable treatments in Diabetic Macular Edema (DME), where DURAVYU has shown promising Phase 2 results.

Comparison to Industry Standards

• DURAVYU's Phase 3 trials (LUGANO and LUCIA) are designed as non-inferiority studies comparing DURAVYU 2.7mg to an on-label aflibercept control, which is a widely used current standard of care for wet AMD.
• The 6-month redosing schedule being evaluated for DURAVYU contrasts significantly with the average two-month dosing of current anti-VEGF treatments like aflibercept in the U.S., offering potential for greater clinical flexibility and improved patient compliance.
• The patient-centric design and real-world approach of the trials, approved by both U.S. and European regulatory bodies, aim to generate data highly relevant to clinical practitioners.
• DURAVYU's mechanism of action as a selective and potent tyrosine kinase inhibitor (TKI) that works intracellularly to inhibit all VEGF receptors is differentiated from large molecule anti-VEGF treatments that typically target only one pathology of the disease.
• Phase 2 DAVIO 2 data for wet AMD demonstrated statistically non-inferior BCVA compared to on-label aflibercept and an impressive 80%+ reduction in treatment burden.
• Phase 2 VERONA data for DME showed rapid and sustained improvement in vision and anatomical control with fewer injections compared to standard of care, positioning DURAVYU to provide an improved DME treatment paradigm.

Management Changes

Legal Proceedings

• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorneys Office for the District of Massachusetts.
• Uncertainties regarding the FDA warning letter pertaining to the Watertown, MA manufacturing facility.

Stakeholder Impact

• Shareholders: Positive impact due to significant de-risking of the lead product candidate (DURAVYU) by completing pivotal Phase 3 enrollment ahead of schedule, potentially increasing confidence in future regulatory approval and commercial success.
• Patients (Wet AMD/DME): Potential for a new, more durable treatment option (6-month redosing) that could significantly reduce treatment burden, improve compliance, and maintain visual function more effectively than current therapies.
• Physicians/Retinal Community: DURAVYU's patient-centric design and potential for reduced injection frequency could offer greater clinical flexibility and resonate with practitioners seeking improved treatment paradigms.
• Employees: Continued progress in clinical development and manufacturing could provide job security and growth opportunities.

Next Steps

• Anticipated topline 56-week data for LUGANO trial in mid-2026.
• Topline data for LUCIA trial to follow closely after LUGANO.
• Planning for Phase 3 pivotal program for DME in 2026.
• Continued focus on bringing the first sustained-release TKI for wet AMD to market.
• Advancing the mission of delivering transformative treatment options for patients.

Key Dates

Recommendation

The completion of pivotal Phase 3 trial enrollment for DURAVYU in wet AMD, significantly ahead of schedule, is a major de-risking event for EyePoint Pharmaceuticals. This milestone, coupled with positive interim safety data and a strong cash runway into 2027, substantially increases the probability of regulatory success and future commercialization. The rapid enrollment pace indicates strong physician and patient interest in a sustained-release therapy, highlighting the significant unmet need DURAVYU aims to address. Furthermore, the positive Phase 2 results and planned Phase 3 for DME provide additional pipeline value. While inherent risks in drug development remain, the current progress positions EyePoint favorably, making it a compelling "strong buy" for investors seeking exposure to innovative retinal disease therapeutics.

Keywords

EyePoint Pharmaceuticals, EYPT, DURAVYU, wet AMD, age-related macular degeneration, diabetic macular edema, DME, Phase 3, clinical trials, LUGANO, LUCIA, vorolanib, Durasert E, sustained release, TKI, anti-VEGF, retinal disease, ophthalmology, biopharmaceutical, FDA, EMA, clinical development